Neeraj Agarwal: Congrats Shilpa Gupta for oral ASCO 2025 Abstract on mUC Bladder Cancer
Neeraj Agarwal, Professor of Medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:
“Congrats Shilpa Gupta for oral abstract #4502 ASCO25
In the Ph3 EV-302 trial in mUC bladder cancer, patients achieving a CR had higher PFS and OS with EV+P vs. chemo (exploratory analysis)”
Abstract Title: Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Authors: Shilpa Gupta, Jens Bedke, Michiel Van Der Heijden, Begoña Valderrama, Eiji Kikuchi, Jeannie Hoffman-Censits, Gopa Iyer, Christof Vulsteke, Steffen Rausch, Se Hoon Park, Alexandra Drakaki, Waddah Arafat, Umang Swami, Ignacio Duran, Jian-Ri Li, Blanca Homet Moreno, Seema Gorla, Xuesong Yu, Yi-Tsung Lu, Thomas Powles
Read Full Abstract on ASCO.
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023